Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma [0.03%]
具有MYC重排和正常MYC的生发中心B细胞弥漫性大B细胞淋巴瘤的选择性增强子依赖性
Ashwin R Iyer,Aishwarya Gurumurthy,Shih-Chun A Chu et al.
Ashwin R Iyer et al.
High expression of MYC and its target genes identify germinal center B-cell diffuse large B-cell lymphomas (GCB-DLBCL) associated with poor outcomes. We used CRISPR-interference profiling of human lymphoma cell lines to define essential enh...
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma [0.03%]
淋巴瘤治愈性联合疗法临床试验的肿瘤内和患者间异质性模型解释
Amy E Pomeroy,Adam C Palmer
Amy E Pomeroy
Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patient outcomes, especially for curative treatments. We...
SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity [0.03%]
SOCS1保护异基因T细胞介导的细胞毒性对急性髓系白血病的作用
Enoch Tin,Sergio Rutella,Ismat Khatri et al.
Enoch Tin et al.
Despite the curative potential of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (AML), its efficacy is limited by intrinsic resistance of cancer cells to donor-derived T-cell cytotoxicity. Using a genome-wide...
Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma [0.03%]
复发和难治性套细胞淋巴瘤中倍林妥莫双抗与异基因造血干细胞移植的对比研究
Nora Liebers,Ariane Boumendil,Hervé Finel et al.
Nora Liebers et al.
Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an an...
High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study [0.03%]
高剂量甲氨蝶呤、伊布替尼和替莫唑胺治疗新诊断的原发中枢神经系统淋巴瘤：一项多中心前瞻性II期研究
Yan Gao,Liqin Ping,Changguo Shan et al.
Yan Gao et al.
Genetic alterations of chronic active B-cell receptor signaling often occur in primary central nervous system lymphoma (PCNSL). We conducted a phase-II trial of high-dose methotrexate plus ibrutinib and temozolomide (MIT) in the treatment o...
Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach [0.03%]
从基因到 outreach：应对血液系统恶性肿瘤的健康差异
Christopher R Flowers,Rachel W Anantha,Veronica Leautaud et al.
Christopher R Flowers et al.
This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the nee...
Increased clonal hematopoiesis in long-term survivors of pediatric hematopoietic cell transplantation [0.03%]
儿童造血细胞移植长期生存者的克隆性血液增多
Konradin F Müskens,Nienke Wieringa,Maaike G J M van Bergen et al.
Konradin F Müskens et al.
In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. Here, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT sur...
Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma [0.03%]
CAR-T细胞产品在大B细胞淋巴瘤中的免疫重建动力学和对结果的影响
Danny Luan,Susan DeWolf,Teng Fei et al.
Danny Luan et al.
Patients treated with chimeric antigen receptor T-cell (CAR-T) therapy are subject to profound immune suppression. Dynamics of immune reconstitution (IR) and impacts of IR on outcomes following infusion across CAR-T products are not well un...
The crossroads of clonal evolution, differentiation hierarchy and ontogeny in leukemia development [0.03%]
克隆演化、分化层级和发育在白血病发病机制中的交汇点
Christopher M Sturgeon,Elvin Wagenblast,Franco Izzo et al.
Christopher M Sturgeon et al.
Transformative technologies to sequence tumor genomes at large scale and single-cell resolution have exposed the repertoire of genetic alterations that are present in leukemia genomes, the timing of their acquisition and patterns of their c...